A much-anticipated "cross-sector rescue" has collapsed almost as quickly as it began, leaving Guangdong Biolight Meditech Co.,Ltd. (300246.SZ) facing a host of unresolved challenges. The company announced late on August 9, 2026, that it had terminated plans to change its controlling shareholder, bringing a dramatic week-long saga to an abrupt end. Shares plunged by the 20% daily limit upon resumption of trading, with the stock closing at 15.41 yuan and the company's market value dropping from 5.096 billion yuan to 4.078 billion yuan in a single session—erasing over 1 billion yuan in shareholder wealth as more than 150,000 sell orders piled up at the limit-down price.

The aborted handover is the latest chapter in a story of a veteran medical device maker that has now lost money for four consecutive years, a controlling shareholder who has been cashing out while the company bleeds, and a capital narrative centered on hopes of a "chip backdoor listing" that ultimately failed to materialize.

Margins Shrink, Losses Reach 260 Million Yuan Over Four Years

Founded in Zhuhai in 1993 and listed on the ChiNext board in 2011, Guangdong Biolight Meditech Co.,Ltd. has long been a domestic pioneer in multi-parameter patient monitors. The company operates across three segments: life information and support, kidney disease care, and broader healthcare products, with its portfolio including monitors, hemodialysis equipment, and related consumables. Yet the firm has been mired in persistent losses in recent years.

From 2022 through 2025, the company's net profit excluding non-recurring items stood at -6.66 million yuan, -81.50 million yuan, -96.54 million yuan, and -79.16 million yuan respectively, accumulating losses exceeding 260 million yuan over the four-year period. The downturn has continued into 2026, with first-quarter revenue of 243 million yuan, down 1.91% year-on-year, and a net loss of 7.32 million yuan attributable to shareholders. The loss excluding non-recurring items widened to 14.63 million yuan during the quarter.

The company has attributed its struggles to intensifying market competition and price cuts from centralized procurement of hemodialysis consumables, which have lowered selling prices while raw material costs have risen, squeezing gross margins. Gross margin has eroded from 32.43% in 2023 to 25.70% in 2025. According to Wind data, the average gross margin for the 70 listed companies in the A-share healthcare equipment industry was 53.08% in 2025—meaning Biolight's margin is less than half the industry average. The company is also among the few in its sector with a negative return on equity, posting an ROE of -5.89% in 2025, ranking near the bottom of its peer group, while the industry average ROE stood at 4.43% and the median at 7.08%.

From a shareholder return perspective, Biolight has accumulated net profits of 629 million yuan since its listing, while raising 1.02 billion yuan through its IPO, private placements, and convertible bonds. Total dividends paid out amount to just 257 million yuan, meaning the company has raised four times more capital than it has returned to shareholders. For a company that continuously draws from the market without generating meaningful positive returns, questions about its investment value are inevitable.

Controlling Shareholder Moves From Selling Down to Seeking an Exit

Amid the company's prolonged losses, the divestment activities of controlling shareholder Yan Jinyuan and his concert party Wang Shi—who are married—have drawn considerable attention. Yan's selling began in earnest in 2020, when he disposed of shares through concentrated竞价 trading between March and June, pocketing 55.37 million yuan. In September of that same year, the couple also sold convertible bonds, generating estimated profits of between 6 million and 13 million yuan. Although a reduction plan disclosed in 2021 was eventually terminated early, the pace of selling accelerated sharply in 2026.

On January 12, 2026, Yan and Wang signed a share transfer agreement with Zhejiang Quwei Zhihc Holding Partnership (L.P.), transferring a combined 18.52 million shares—representing 7% of the company's total share capital—at a price of 9.45 yuan per share, for a total transaction value of approximately 175 million yuan. The transfer was completed on May 28. Following the transaction, Yan's stake fell from 26.72% to 20.58%, and Wang's from 2.46% to 1.60%, bringing their combined holdings to 22.18%.

From 2020 through the first half of 2026, the couple has cashed out more than 230 million yuan through share and convertible bond sales. Remarkably, just two months after completing this large-scale reduction, Yan initiated plans for a change in control—had the handover succeeded, even selling half of his remaining stake would have fetched approximately 600 million yuan at prevailing market prices.

Second-Largest Shareholder Enters, Founders Join the Board

The market's intense interest in this ownership change stems largely from the unusual background of the new second-largest shareholder, Quwei Zhihc. Established in September 2025, the partnership's largest partner, Hangzhou Weigu Digital Technology Co., Ltd., is wholly owned by Weigu Information Technology (Quzhou) Co., Ltd., a company specializing in solid-state storage chips, including chip-level storage and embedded storage products used in high-end applications such as vehicles, ships, aviation, and aerospace. Weigu Information has completed multiple financing rounds backed by prominent investors including Shenzhen Capital Group and Qianhai Fund.

On June 29, 2026, just one month after the share transfer was completed, Biolight and Zhejiang Shenglou Investment Management Co., Ltd. jointly established Zhuhai Weibao Technology Co., Ltd., with Biolight holding 51% and the new entity's business scope covering integrated circuit chip and product sales. For a company that had spent three decades in medical devices to suddenly venture into the storage chip arena fueled market speculation that the potential buyer behind the ownership change was indeed the Quwei Zhihc system.

Driven by strong expectations of a "chip backdoor listing," Biolight's share price climbed steadily throughout 2026, surging 137.78% by the time trading was suspended on July 31. In the final trading session before the suspension, the stock jumped 10.37% to close at 19.26 yuan. However, with the abrupt termination of the ownership change, those hopes were dashed—Biolight remains a medical device company with four consecutive years of losses, and Weigu Information's path to a backdoor listing has been temporarily blocked.

Just as the market assumed the "chip backdoor" story had concluded, a new twist emerged: two co-founders of Weigu Information were nominated to join Biolight's board. On August 14, after market close, Biolight announced that it had received resignation letters from directors Zhang Daoguo and Xu Wei. Zhang resigned as a non-independent director but will continue as vice president and general manager of the active manufacturing systems division; Xu resigned as a non-independent director but will remain as CFO and head of the finance systems division. Both had served as directors since 2016 and 2017 respectively, making the timing of their resignations—at the sensitive moment following the aborted ownership change—highly conspicuous.

Simultaneously, Biolight's board proposed nominating Wu Jia and Liu Jia as non-independent directors for the ninth board term. According to their bios, Wu Jia, born in 1982, founded Weigu Information in 2013 and currently serves as its founder, chairman, and president. Liu Jia, also born in 1982, has served as co-founder and vice president of Weigu Information since 2017.

It must be emphasized that board seats and control are two different matters. Yan and Wang currently hold a combined 22.18% stake, retaining their position as the largest shareholder, while Quwei Zhihc holds 7% as the second-largest shareholder. Two non-independent director seats may provide some voice, but they fall far short of substantive control over the company. Whether Weigu Information harbors further ambitions—such as additional equity accumulation—warrants close monitoring.

Additionally, according to Tianyancha, Quwei Zhihc was placed on the operating anomaly list by the Quzhou Municipal Market Supervision Administration on July 1, 2026, for failing to publicly disclose its 2025 annual report within the required timeframe as stipulated by Article 8 of the Interim Regulations on Enterprise Information Disclosure. As of this writing, the entity has not been removed from the list.

Multiple Risks Converge After the Collapsed Handover

The failed ownership change has unleashed consequences far beyond the share price plunge. First, governance stability is now in question. The controlling shareholder's pattern—first reducing his stake by 7%, then attempting to transfer control without success—has raised deep concerns about corporate governance reliability. With Yan and Wang now holding just 22.18% combined, any further reduction would make the question of who controls the company even more uncertain.

Second, convertible bond repayment pressure is imminent. The "Baolai Convertible Bond" matures on September 3, 2026, with a redemption price of 115 yuan per bond. As of the end of the second quarter of 2026, approximately 2.18 million bonds remained outstanding. While the current share price has recovered to above the conversion price of 18.30 yuan (trading at 18.80 yuan intraday as of August 19), the premium is extremely thin, and with only three weeks until maturity, there is considerable uncertainty about whether the share price can hold at current levels. If the stock falls below the conversion price at maturity, conversion rates will remain low, and the company will face significant repayment obligations.

Third, the operational fundamentals have shown no sign of improvement. As of the first quarter of 2026, the company remains loss-making, and the trend of centralized procurement price cuts for hemodialysis consumables is unlikely to reverse in the near term. Although the National Health Commission has announced plans to add 350 new primary-level medical institutions offering hemodialysis services this year, whether this policy dividend translates into actual performance for Biolight remains to be seen.

According to a 2026 tracking rating report issued by China Chengxin Securities Rating on Biolight's bonds, the company's credit outlook was revised to negative, citing not only operational pressure but also "increased short-term debt pressure, ongoing risk of accounts receivable write-offs and asset impairment, and persistently insufficient overall capacity utilization." As of the end of the first quarter of 2026, Biolight held 577 million yuan in cash and wealth management products, while its interest-bearing debt had reached 666 million yuan, including 114 million yuan in short-term borrowings, 304 million yuan in non-current liabilities due within one year, 222 million yuan in long-term borrowings, and 25.55 million yuan in lease liabilities.

From planning to termination: just one week. From 19.26 yuan to 15.41 yuan: just one trading day. Biolight's "ownership change drama" has concluded with 1 billion yuan in market value erased and investors deeply trapped. Looking back at the full sequence of events, the controlling shareholder's decision to cash out 175 million yuan while the company was in its fourth consecutive year of losses, before attempting a complete exit, inevitably raises questions about both motive and timing. Meanwhile, the market's fervor for the "chip backdoor" concept reflected a deeper disappointment with the fundamentals of a loss-making company—whenever there is even a glimmer of hope for transformation, capital rushes in.

Now that expectations have been dashed, Biolight must confront the realities before it: persistent losses, imminent convertible bond redemption, increasingly dispersed shareholding, and a "cross-sector story" that has been thoroughly exhausted in the capital markets. For investors holding Biolight shares, this may not be the end of the risk—it may simply be the beginning of a new round of tests.